Researchers at Insilico Medicine in Massachusetts announced that rentosertib, a drug being developed for idiopathic pulmonary fibrosis (IPF), may have an unexpected benefit: it appears to make patients biologically younger. In a pilot study of 42 IPF patients, blood‑protein analysis showed a shift equivalent to three to four years of reduced biological age, with one participant showing a six‑year reduction.
Study design and findings
The 12‑week trial compared rentosertib to a placebo. Participants received 30 mg of the drug twice daily for four weeks. Six independent aging clocks—validated tests that estimate biological age from blood markers—consistently indicated younger scores for the treatment group. When the researchers matched the protein changes against data from more than 55,000 individuals in the UK Biobank, the direction of change was opposite to the normal aging trajectory.
Lead author Alex Zhavoronkov, PhD, founder and co‑CEO of Insilico Medicine, described the result as a “promising trend in age reversal” that emerged as a bonus while pursuing the primary goal of treating lung scarring. He cautioned that the findings are preliminary and do not yet prove that rentosertib can extend lifespan or prevent age‑related disease.
Safety and next steps
Dr. Carol Ann Satler, senior vice president of clinical development for Insilico, said the drug’s side‑effect profile was manageable. The most common adverse events were mild diarrhea, modestly reduced potassium levels, and temporary elevations in liver enzymes, all of which returned to normal after discontinuation.
Based on these early results, Insilico is moving rentosertib into a phase 3 trial involving more than 300 patients in China. The larger study will include longer treatment periods and will enroll participants without IPF to determine whether the observed protein changes translate into genuine anti‑aging effects.
Context and expert perspective
While the data are intriguing, experts stress that biological‑age clocks are still emerging tools. “It’s early days,” Zhavoronkov noted, and the research community will need larger, longer‑term trials to confirm any real impact on healthspan.
Nevertheless, the study illustrates how artificial‑intelligence‑driven drug discovery can uncover unexpected benefits. Insilico’s approach seeks “molecular criminals”—targets that contribute to both disease and aging—and rentosertib may be the first example of a therapy that tackles both.
Implications for patients
For individuals living with IPF, the primary benefit remains the potential to slow lung scarring, a serious condition that can lead to respiratory failure. If future trials confirm the anti‑aging signal, rentosertib could become a dual‑purpose medication, offering both disease‑modifying and health‑span‑extending effects.
Until then, clinicians and patients should view the findings as an encouraging hypothesis rather than a proven treatment for aging.
Original reporting: Fox News (HLL/CB) — read the source article.
